Table 1.

COVID vaccines granted an Emergency Use Authorization (EUA) by Federal Drug Administration (FDA) and/or Emergency use listing (EUL) by WHO.

	Pfizer/BioNTech	Moderna	Janssen	Oxford/AstraZeneca	Sinopharm	SinoVac
Target Population	Age 12 and older	Age 18 and older
Vaccine Administration	2 doses, 21 days apart	2 doses, 28 days apart	1 dose	2 doses, 8 to 12 weeks apart	2 doses, 21 to 28 days apart
Efficacy	95%	94.1%	72% overall and 86% against severe disease	63.1%	73%	83.5%
Side effects	Most common—injection site pain, fatigue, headache, muscle pain, joint pain, & fever
	More common after the second dose		-	More common after the second dose
	Rare—Severe allergic reaction Bell’s palsy, myocarditis, & pericarditis		Rare—TTS, post-vaccination syndrome, radiculitis, GBS		N/A	N/A
Safety in Pregnant/Lactating women	Animal Studies—No safety concerns				Animal Studies -N/A
	Human Studies—N/A

N/A—Not Available, GBS—Guillain-Barre syndrome, TTS—thrombosis with thrombocytopenia syndrome.